Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057117 | 0.87 | TDP1 (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL8066511 | 0.84 | TDP1 (0.59) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL312287 | 0.83 | KMT2A (0.92) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL22644297 | 0.83 | KMT2A (0.71) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL12369119 | 0.81 | ALDH1A1 (0.48) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL8870777 | 0.81 | ALDH1A1 (0.68) | KMT2ATDP1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL6430828 | 0.81 | KMT2A (0.63) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL813539 | 0.80 | TSHR (0.47) | KMT2ATDP1SLC6A2LMNAALDH1A1 | |
| Benzyl Benzoate SCHEMBL3038 | 0.80 | KMT2A (1.00) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL8010992 | 0.80 | KMT2A (1.00) | KMT2ATDP1SLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-06 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | KMT2A 3492/4885TDP1 1233/4885SLC6A2 2556/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | KMT2A 1851/4885TDP1 3222/4885SLC6A2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.